THE CAR-T TREATMENT TIMELINE:
LEUKAPHERESIS TO DISCHARGE
Understanding every phase of CAR-T therapy — from the day T cells are collected to the day you go home — reduces uncertainty and helps patients and families prepare effectively.
analyticsAt a Glance
- check_circleTotal CAR-T timeline: typically 6–10 weeks from leukapheresis to discharge
- check_circleManufacturing takes 3–5 weeks — bridging therapy is required to control disease during this period
- check_circlePost-infusion hospital stay for CRS and ICANS monitoring: typically 14–21 days
- check_circleCancerFax provides patients with a detailed personalised timeline and day-by-day support throughout
The CAR-T Journey: An Overview
CAR-T therapy is not a single appointment — it is a structured, multi-phase treatment journey that takes 6–10 weeks from start to discharge. Understanding the full arc of this journey — including the manufacturing gap, the hospital admission, and the post-infusion monitoring period — allows patients and families to plan logistically, emotionally, and financially before the process begins.
“The most effective CAR-T patients are the ones who knew what to expect. The manufacturing wait, the conditioning, the CRS — none of it is less challenging with preparation, but all of it is manageable.”
Why the Timeline Is Longer Than Other Cancer Treatments
Unlike chemotherapy infusion (a few hours, same day) or radiotherapy (daily over weeks), CAR-T requires personalised manufacturing of a living cell product from the patient's own T cells. This manufacturing process takes 3–5 weeks — an unavoidable gap between T cell collection and the treatment being ready to infuse.
What Happens in Each Phase
The CAR-T journey has five phases: (1) Pre-leukapheresis preparation; (2) Leukapheresis — T cell collection; (3) Manufacturing and bridging therapy; (4) Lymphodepletion conditioning and infusion; (5) Post-infusion monitoring and discharge planning. Each phase has specific patient responsibilities and clinical milestones.
The Complete CAR-T Timeline: Phase by Phase
A detailed walkthrough of every phase of the CAR-T process — what happens clinically, what the patient experiences, and how long each phase typically takes.
- 1
Phase 1: Pre-Leukapheresis Assessment (Days –14 to –1)
Comprehensive baseline assessment: bone marrow biopsy confirming diagnosis and target antigen expression; CT/PET-CT staging; blood counts and organ function panel (LVEF, renal, hepatic, pulmonary); infectious screening (HIV, hepatitis B/C, CMV, EBV); performance status assessment. Consent process and patient education about the full CAR-T pathway.
- 2
Phase 2: Leukapheresis — T Cell Collection (Day 0)
An outpatient or day-case procedure lasting 3–5 hours. A central venous catheter or large-bore peripheral IV is used to process 10–15 litres of blood through an apheresis machine, separating mononuclear cells (including T lymphocytes) and returning the rest of the blood to the patient. The collected cells are cryopreserved and shipped to the CAR-T manufacturing facility.
- 3
Phase 3: Manufacturing Gap + Bridging Therapy (Days 1–28 to 42)
The T cells are genetically engineered with the CAR construct, expanded under GMP conditions, quality-tested, and cryo-shipped back to the infusion centre. This takes 3–5 weeks. During this period the patient continues bridging therapy — disease-controlling treatment to prevent significant progression. Bridging should be effective but not lymphotoxic (avoid prolonged high-dose steroids). Common bridging regimens: pola-BR (lymphoma), daratumumab + dex (myeloma), blinatumomab or steroid-based (ALL).
- 4
Phase 4a: Pre-Infusion Assessment and Travel (Days 33–42)
Patient travels to the CAR-T centre 10–14 days before planned infusion for final pre-infusion assessment. Repeat bone marrow biopsy and/or CT/PET staging to confirm disease status. Confirm adequate organ function for conditioning. Infectious prophylaxis started (co-trimoxazole or pentamidine for PCP, antifungal, antiviral prophylaxis).
- 5
Phase 4b: Lymphodepletion Conditioning (Days –5 to –1)
Standard conditioning: fludarabine 25–30 mg/m²/day IV + cyclophosphamide 300–500 mg/m²/day IV for 3 consecutive days (days –5 to –3), then 2 rest days. Some myeloma protocols use modified conditioning. Lymphodepletion removes endogenous T cells and creates immunological 'space' that promotes CAR-T engraftment and in vivo expansion. Patients typically require anti-emetics, hydration, and blood count monitoring.
- 6
Phase 4c: CAR-T Infusion (Day 0 of Infusion)
The thawed CAR-T product is infused IV over 30–60 minutes — the infusion itself is brief. Vital signs are monitored closely during and for 4 hours after infusion. CRS symptoms typically begin 1–14 days post-infusion as the CAR-T cells start expanding and releasing cytokines. Patients are admitted for the monitoring period.
- 7
Phase 5: Post-Infusion Monitoring and Discharge (Days 1–21 post-infusion)
Hospital admission for CRS and ICANS monitoring: typically 14–21 days. CRS management: fever, hypotension, hypoxia managed with tocilizumab (IL-6 blocker) and corticosteroids. ICANS monitoring: daily neurological assessment — confusion, speech changes, seizure require escalation. Day 28 response assessment: bone marrow biopsy + MRD testing. Discharge when CRS ≥Grade 2 has resolved and patient is clinically stable.
CAR-T Timeline at a Glance
A condensed reference guide to the entire CAR-T timeline — suitable for sharing with family members, employers, or healthcare coordinators.
| Phase | When | Duration | Patient Location | Key Event |
|---|---|---|---|---|
| Pre-leukapheresis assessment | Weeks –2 to –1 | 1–2 weeks | CAR-T centre or local hospital | Baseline biopsy, staging, consent |
| Leukapheresis (T cell collection) | Day 0 | 1 day | CAR-T centre (outpatient) | T cells collected and shipped to manufacturer |
| Manufacturing gap + bridging therapy | Days 1–28 to 42 | 3–5 weeks | Home or local treatment centre | Bridging therapy; awaiting manufactured product |
| Travel to CAR-T centre + pre-infusion workup | Days 33–42 | 5–10 days | CAR-T centre | Final staging, infectious prophylaxis |
| Lymphodepletion conditioning | Days –5 to –3 before infusion | 3 days chemo + 2 rest days | Inpatient at CAR-T centre | Fludarabine + cyclophosphamide |
| CAR-T infusion | Day 0 of infusion | 30–60 minutes | Inpatient at CAR-T centre | IV infusion; CRS monitoring begins |
| Post-infusion monitoring | Days 1–21 post-infusion | 14–21 days | Inpatient or close outpatient at CAR-T centre | CRS/ICANS management; Day 28 MRD assessment |
| Discharge planning and return home | Days 21–30 post-infusion | 3–7 days | CAR-T centre then home | Discharge documentation; home haematologist briefing |
Post-Infusion Monitoring: What the Numbers Mean
Key statistics from CAR-T clinical series describing CRS, ICANS, and response assessment timelines — the data that defines what patients should expect post-infusion.
- Day 2–7Median onset of cytokine release syndrome (CRS) after CAR-T infusionCRS typically begins 2–7 days after infusion — as CAR-T cells encounter tumour cells and begin expanding and releasing inflammatory cytokines. Higher disease burden at infusion is associated with earlier and more severe CRS.
- 60–80%Patients experiencing any-grade CRS (most Grade 1–2)The majority of CAR-T recipients experience some degree of CRS — typically low-grade fever, fatigue, and mild inflammatory symptoms. Grade 3+ CRS (hypotension requiring vasopressors, significant respiratory compromise) occurs in 5–15% and requires tocilizumab and/or corticosteroids.
- Day 28Standard first response assessment timepoint after CAR-T infusionBone marrow biopsy with MRD testing at day 28 is the standard first assessment of CAR-T response — both for leukaemia (ALL, CLL) and for myeloma (bone marrow plasma cell assessment). Early MRD-negative status is the strongest predictor of durable response.
CRS and ICANS: What Patients Need to Know
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the two principal acute toxicities of CAR-T therapy. Understanding them reduces fear and enables earlier reporting of symptoms.
Cytokine Release Syndrome (CRS)
- What it is: fever, inflammation, hypotensionCRS is caused by massive cytokine release from activated CAR-T cells and bystander immune cells. Symptoms range from low-grade fever and fatigue (Grade 1) to high fever, low blood pressure, and low oxygen levels requiring intensive care (Grade 3–4). It is the most common CAR-T toxicity.
- When it occurs: Days 2–14 post-infusionMost CRS begins within the first week after infusion — coinciding with peak CAR-T expansion. It typically resolves within days of treatment with tocilizumab (IL-6 blockade) and/or corticosteroids.
- Management: tocilizumab first, steroids for refractoryGrade 2+ CRS is treated with tocilizumab (8 mg/kg IV). Grade 3 adds dexamethasone. Grade 4 requires ICU-level support. Most cases resolve within 24–72 hours of treatment initiation at experienced centres.
ICANS (Neurotoxicity)
- What it is: confusion, speech changes, seizureICANS is a neurological toxicity — characterised by confusion, word-finding difficulty, handwriting changes, disorientation, and in severe cases, seizures or cerebral oedema. It can overlap with CRS or occur after CRS has resolved.
- When it occurs: Days 4–21 post-infusionICANS can occur during or after CRS — typically within the first 3 weeks of infusion. Daily neurological assessment using the ICE score is performed during the monitoring period at all CAR-T centres.
- Management: dexamethasone ± anti-seizure medicationGrade 2+ ICANS is treated with dexamethasone. Grade 3–4 requires high-dose methylprednisolone and often anti-seizure prophylaxis. ICANS does not respond to tocilizumab — steroid escalation is the primary treatment.
Frequently Asked Questions
Common questions from patients and families about preparing for and living through the CAR-T process.
About the CAR-T Timeline and Preparation
What should I bring to China for my CAR-T treatment stay?
CancerFax provides each patient with a personalised pre-travel preparation checklist. Essential items: a complete printed and digital copy of all medical records in English; 90 days' supply of all regular medications (confirm each is safe to continue with your haematologist); comfortable clothing for extended hospital stay; entertainment and communication devices (VPN recommended for international internet access in China); health insurance documentation; and emergency contact details. CancerFax coordinates accommodation near the treating centre for accompanying family members.
Can my family member accompany me for the CAR-T process?
Yes — and it is strongly recommended. One companion is advised for the entire stay. CancerFax arranges family accommodation near the treating centre, provides daily updates to the family through the bilingual coordinator, and coordinates communication with family members remaining in the home country. The treating centre can accommodate family visitors during the hospital admission within standard visiting protocols.
What happens if my disease progresses rapidly during the manufacturing gap?
Rapid disease progression during manufacturing is the most challenging scenario in CAR-T planning. Options include intensifying bridging therapy, adding radiation for focal problematic lesions, and in some cases requesting expedited manufacturing (not always feasible). CancerFax maintains communication with the manufacturing facility and the CAR-T centre throughout the manufacturing period to flag any emerging urgency. Patients with very rapidly progressive disease at the time of leukapheresis should discuss alternative bridging strategies and realistic timelines with their haematologist before committing to CAR-T.
How do I manage ongoing monitoring after returning home from CAR-T?
CancerFax prepares a comprehensive discharge package — including bone marrow biopsy results at day 28, response assessment imaging, medication list, infectious prophylaxis schedule, immunoglobulin replacement instructions (if applicable), and a structured letter for the home haematologist with recommended monitoring intervals and MRD assessment dates. Subsequent bone marrow assessments (day 60, day 100, day 180) can be performed locally with results shared with the Chinese CAR-T team through CancerFax.
More from the CAR-T Cell Therapy Resource Library
Explore the complete CAR-T guide library — from targets and products to disease-specific eligibility.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
CancerFax Guides You Through Every Step of the CAR-T Process
CancerFax provides each patient with a personalised CAR-T timeline, pre-travel preparation checklist, and dedicated bilingual coordinator support throughout the entire process — from eligibility assessment to post-discharge follow-up coordination with the home haematologist.
This content is for informational purposes only. Your specific CAR-T timeline will be personalised by your treating haematologist and the CAR-T centre team.